Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Novartis announced an agreement to acquire Myricx Bio, a UK biotech focused on a new class of antibody-drug conjugates (ADCs) using N-myristoyltransferase inhibitor (NMTi) payloads. The deal signals strategic expansion of Novartis’ ADC platform, which is likely to be viewed as a positive growth catalyst, though the article provides no disclosed financial terms or timeline.

Analysis

Novartis announced an agreement to acquire Myricx Bio, a UK biotech focused on a new class of antibody-drug conjugates (ADCs) using N-myristoyltransferase inhibitor (NMTi) payloads. The deal signals strategic expansion of Novartis’ ADC platform, which is likely to be viewed as a positive growth catalyst, though the article provides no disclosed financial terms or timeline.